The PennZone

  • Home
  • Business
  • Health
  • Non-profit
  • Technology
  • Services
  • Music
  • Entertainment
  • Travel

MYONEX ANNOUNCES ACQUISITION OF SAVEWAY COMPOUNDING PHARMACY TO EXPAND ITS CLINICAL TRIAL SERVICES ACROSS THE US USA - English USA - español USA - English
The PennZone/10266682

Trending...
  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026
  • Bent Danholm Joins The American Dream TV as Central Florida Host
  • NAFMNP Awarded USDA Cooperative Agreement to Continue MarketLink Program Under FFAB
HORSHAM, Pa., April 9, 2024 ~ Myonex, a leading global clinical trial supply company, has recently announced the completion of its acquisition of SaveWay Compounding Pharmacy in Newark, Delaware. The pharmacy will now operate as SaveWay Compounding Pharmacy, a Myonex company.

This strategic move by Myonex is part of their ongoing efforts to support clinical trial sponsors' trial designs with direct-to-patient (DTP) and home healthcare provider (HHP) capabilities. With this acquisition, Myonex aims to provide wider patient access across the entire United States and support patients in obtaining the necessary trial medication and equipment.

According to James Lovett, Chief Executive Officer at Myonex, "SaveWay's pharmacy capabilities complement and extend our existing clinical supplies solutions within the US. SaveWay will provide additional access for drug sourcing and direct-to-patient options across all 50 states for our clinical packaging and labeling and ancillary supply services." This will also complement Myonex's market-leading CTRx™ to offer a full suite of prescription-based supply options for both investigational medicinal product (IMP) and commercial drug access throughout the US. These added capabilities will enable Myonex to better serve their clients' needs and facilitate decentralized clinical trials (DCT) and hybrid studies.

More on The PennZone
  • CredHub and Real Property Management Join Forces to Empower Franchise Owners with Rental Payment Credit Reporting Solutions
  • Leimert Park Announces Weeklong Kwanzaa Festival & Kwanzaa Parade Celebrating Black History, Culture, and Community
  • Schmuck Lumber Ace Hardware Opens New Greenhouse Addition
  • Renowned Alternative Medicine Specialist Dr. Sebi and His African Bio Mineral Balance Therapy Are the Focus of New Book
  • Psychiatric Drug Damage Ignored for Decades; CCHR Demands Federal Action

The acquisition also presents an opportunity for SaveWay to expand into the realm of clinical trials and accelerate the growth of their direct-to-patient services. Pradeep Chilakapati, RPh, Managing Partner and Pharmacist at SaveWay, expressed excitement about this partnership: "We welcome the opportunity to be part of an experienced clinical trial supply company with its roots in pharmacy. Myonex understands how we work and what we can offer to support today's trends in clinical trials."

This recent acquisition announcement comes on the heels of another significant acquisition by Myonex – that of Creapharm – further solidifying their commitment to providing faster, more flexible, and reliable services to their clients while improving the clinical trial patient experience. With these acquisitions, Myonex now boasts one of the most diverse clinical trial supply service offerings globally.

Myonex was exclusively advised by Crosstree as its financial advisor and Troutman Pepper as its legal advisor in this acquisition of SaveWay. This partnership is expected to bring about significant growth and success for both companies in the clinical trial supply industry.
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Top Tips for Hiring HVAC Contractors in Philadelphia
  • Harry Hayman of Feed Philly Coalition Proudly Supports Sharing Excess' Holiday Food Rescue — Bri
  • Virtual Pizza Academy Announces the Return of Two Acclaimed Live Classes in 2026:
  • Teresa James & The Rhythm Tramps announce their new album and debut on MoMojo Records, 'Bad at Being Good'
  • "Micro-Studio": Why San Diegans are Swapping Crowded Gyms for Private, One-on-One Training at Sweat Society
  • Beycome Closes $2.5M Seed Round Led by InsurTech Fund
  • VIP Vacations Invited to Travel Weekly's Annual Readers Choice Awards
  • Tru by Hilton Columbia South Opens to Guests
  • Christy Sports donates $56K in new gear to SOS Outreach to help kids hit the slopes
  • "BigPirate" Sets Sail: A New Narrative-Driven Social Casino Adventure
  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026
  • Women's Everyday Safety Is Changing - The Blue Luna Shows How
  • Microgaming Unveils Red Papaya: A New Studio Delivering Cutting-Edge, Feature-Rich Slots
  • Harry Hayman IV & Gemini Consultants Announce Holiday Toys‑for‑Tots Giveaway with Retired Sixers
  • 5-Star Duncan Injury Group Expands Personal Injury Representation to Arizona
  • The End of "Influencer" Gambling: Bonusetu Analyzes Finland's Strict New Casino Marketing Laws
  • AI-Driven Cybersecurity Leader Gains Industry Recognition, Secures $6M Institutional Investment, Builds Momentum Toward $16M Annual Run-Rate Revenue
  • TRIO Heating, Air & Plumbing Now Ranks #1 in San Jose
  • Milwaukee Job Corps Center Hosts Alumni Day, Calls Alumni to Action on Open Enrollment Campaign
  • Ezra Wohlgelernter Installed Philadelphia Bar Association Chancellor

Popular on PennZone

  • Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders - 1123
  • Light Her Way Launches New Cohort of Board of AdviseHERS to Prepare Women for Board-Ready Leadership - 132
  • UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels
  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026
  • Cyntexa Announces Updates to ChargeOn on Salesforce AppExchange
  • Lineus Medical Receives Patent for SafeBreak® Vascular Generation 2
  • ToneWell Launches AI Wellness Platform with 30-Second Voice-Based Performance Readiness Scan™
  • Escajeda Masonry & Concrete Among Pittsburgh's Fastest-Growing Companies
  • VIP Vacations Wins Diamon Status with AIC Hotel Group
  • T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™

Similar on PennZone

  • Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026
  • Russellville Huntington Learning Center Expands Access to Literacy Support; Approved Provider Under Arkansas Department of Education
  • Pinealage: the app that turns strangers into meditation companions — in crowdfunding phase
  • Women's Everyday Safety Is Changing - The Blue Luna Shows How
  • AI-Driven Cybersecurity Leader Gains Industry Recognition, Secures $6M Institutional Investment, Builds Momentum Toward $16M Annual Run-Rate Revenue
  • Allegiant Management Group Named 2025 Market Leader in Orlando by PropertyManagement.com
  • LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio
  • Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
  • KDG Recognized on the Clutch 1000 List for 2025
  • New Angles US Group Founder Alexander Harrington Receives Top U.S. Corporate Training Honor and Leads Asia-Pacific Engagements in Taiwan
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us